| Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease (NCT03149809) | VA Office of Research and Development | 2018-03-01 |
| The Effect of Low Intensity Extracorporeal Low Energy Shock Wave Therapy on Stress Urinary Incontinence and Overactivity Bladder (NCT04059133) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2018-02-27 |
| Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women (NCT03475706) | Velicept Therapeutics, Inc. | 2018-02-19 |
| Information, Motivation, Behavioral Skills Model on Urinary Incontinence and Quality of Life in Men (NCT04068025) | Ankara Yildirim Beyazıt University | 2018-02-01 |
| Assessment of Potential Biomarkers in Women With Symptoms of Overactive Bladder and Pelvic Organ Prolapse (NCT03516292) | Aristotle University Of Thessaloniki | 2018-01-29 |
| Comparison of Two Forms of Transcutaneous Electrical Stimulation in Overactive Bladder (NCT03742206) | Hospital de Clinicas de Porto Alegre | 2018-01-25 |
| The Efficacy of Botulinum Toxin in OVERACTIVE Bladder (NCT03888001) | Assiut University | 2018-01-01 |
| Tactile Imaging and Electromyography (NCT03477214) | Advanced Tactile Imaging, Inc. | 2017-12-24 |
| Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder (NCT03371342) | Medy-Tox | 2017-12-13 |
| Standardization of Lead Placement for Sacral Neuromodulation Part 2 (NCT03199443) | Universiteit Antwerpen | 2017-10-01 |
| Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. (NCT03175029) | Taiho Pharmaceutical Co., Ltd. | 2017-09-09 |
| Standardization of Lead Placement for Sacral Neuromodulation. Part 1 (NCT03194425) | Universiteit Antwerpen | 2017-09-01 |
| Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence (NCT03643380) | Neuspera Medical, Inc. | 2017-08-17 |
| Sacral Neuromodulation & Urodynamics (NCT03614767) | Universiteit Antwerpen | 2017-08-01 |
| Mirabegron For Erectile Dysfunction (NCT02916693) | Johns Hopkins University | 2017-08-01 |
| Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease (NCT03412513) | Seoul National University Hospital | 2017-07-17 |
| Reproductibility of Cystometry in Multiple Sclerosis Patient (NCT03451175) | Pierre and Marie Curie University | 2017-07-02 |
| Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections (NCT03080389) | The Cleveland Clinic | 2017-07-01 |
| Reliability of KHQ and ICIQ-SF in Assessing Urinary Incontinence Effects in Polish Women (NCT04619238) | Medical University of Lublin | 2017-06-01 |
| Reliability of Polish-Version Overactive Bladder Syndrom Scores (OABSS) (NCT03801239) | Medical University of Lublin | 2017-06-01 |
| Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study (NCT03057158) | Duke University | 2017-05-01 |
| Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy (NCT03213522) | CentraState Medical Center | 2017-04-10 |
| Study of ONO-8577 in Patients With Overactive Bladder (NCT03106623) | Ono Pharmaceutical Co., Ltd. | 2017-04-07 |
| Overactive Bladder Posterior Tibial Implantable MIcro STimulator - 1 (NCT03019094) | BlueWind Medical | 2017-04-01 |
| A Pilot Study Evaluating the Usability of the Oabi Mobile Application (NCT04534946) | Massachusetts General Hospital | 2017-03-20 |
| Effects of Urinary Bladder Hypertrophy on Urge Urine Incontinence After Radical Prostatectomy (NCT03061760) | Collegium Medicum w Bydgoszczy | 2017-03-01 |
| Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial (NCT02873312) | Bioness Inc | 2017-02-10 |
| Sexual Function Trial of Overactive Bladder: Medication Versus PTNS (NCT03500146) | Medstar Health Research Institute | 2017-01-30 |
| Delivery of Intravesical Botulinum Toxin A Using Low Energy Shock Waves in Treatment of Overactive Bladder: A Feasibility Study (NCT03385460) | Mansoura University | 2017-01-24 |
| TTNS vs PTNS in a County Hospital System. (NCT07353944) | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 2017-01-18 |
| Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder (NCT03558919) | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 2017-01-01 |
| Low-level Light Therapy for Overactive Bladder and Urinary Incontinence (NCT02980328) | Seoul National University Hospital | 2016-12-01 |
| Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") (NCT02674269) | UroGen Pharma Ltd. | 2016-10-01 |
| Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need (NCT03136601) | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 2016-10-01 |
| Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing (NCT03625843) | San Antonio Uniformed Services Health Education Consortium | 2016-09-29 |
| PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB (NCT02857816) | MedtronicNeuro | 2016-09-01 |
| Investigation of the Effect of the Female Urinary Microbiome on Incontinence (NCT02835846) | Loyola University | 2016-09-01 |
| A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding (NCT02297178) | Medway NHS Foundation Trust | 2016-08-01 |
| A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment (NCT02240459) | University of Alberta | 2016-08-01 |
| Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. (NCT03575702) | R-Pharm | 2016-07-18 |
| Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (NCT02660359) | Ipsen | 2016-07-08 |
| Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer (NCT02805452) | Center Eugene Marquis | 2016-07-01 |
| A Study of Transcutaneous Electrical Nerve Stimulation for Overactive Bladder (NCT02922842) | University of Rochester | 2016-07-01 |
| Efficacy of Biofeedback PFMT and Medication in Women With Overactive Bladder (NCT04477265) | Far Eastern Memorial Hospital | 2016-06-16 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) (NCT02757768) | Astellas Pharma Global Development, Inc. | 2016-06-13 |
| Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System (RELAX-OAB) (NCT02620410) | Axonics, Inc. | 2016-06-01 |
| A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects (NCT02821312) | Dong-A ST Co., Ltd. | 2016-06-01 |
| Percutaneous Nerve Evaluation With Fluoroscopy Versus Without (NCT02677753) | University of Louisville | 2016-04-01 |
| Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB (NCT03017170) | Weill Medical College of Cornell University | 2016-04-01 |
| Urinary Biomarkers in Overactive Bladder in Children (NCT02704013) | Children's Hospital Zagreb | 2016-04-01 |
| Efficacy of Transcutaneous Nerve Stimulation on Improvement of Overactive Bladder Symptoms (NCT02110680) | Meir Medical Center | 2016-03-01 |
| Urinary Neurotrophin Levels in Healthy Children (NCT02389270) | Children's Hospital Zagreb | 2016-03-01 |
| Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers (NCT02940314) | Hanmi Pharmaceutical Company Limited | 2016-03-01 |
| Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 (NCT02660138) | Ipsen | 2016-03-01 |
| A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB) (NCT02786407) | Lanzhou Institute of Biological Products Co., Ltd | 2016-03-01 |
| Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms (NCT02865395) | Campbell Grant | 2016-03-01 |
| A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) (NCT02656173) | Astellas Pharma Inc | 2016-01-25 |
| A Trial of Transcutaneous Nerve Stimulation for OAB (NCT02511717) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2016-01-01 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) (NCT02526979) | Astellas Pharma Europe B.V. | 2015-12-17 |
| The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides (NCT02524769) | Loyola University | 2015-12-01 |
| Mirabegron in Parkinson Disease and Impaired Cognition (NCT02536976) | HealthPartners Institute | 2015-12-01 |
| Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB (NCT02657057) | Instituto Médico Tecnológico SL | 2015-11-01 |
| Reduction of Bladder Injection Pain With Belladonna Opiate Suppository (NCT02600715) | Edgar LeClaire, MD | 2015-11-01 |
| A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients (NCT02601287) | Allergan | 2015-11-01 |
| Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study (NCT03473782) | NYU Langone Health | 2015-10-12 |
| Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. (NCT02614482) | Stéphane Bolduc | 2015-10-01 |
| The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers. (NCT02494349) | Jeil Pharmaceutical Co., Ltd. | 2015-08-01 |
| Acupuncture on Post-Stroke Overactive Bladder (NCT02568774) | The University of Hong Kong | 2015-08-01 |
| Fall Prevention in Older Adults With OAB (NCT03946124) | University of Pennsylvania | 2015-07-25 |
| Do Patient Anxiety Levels Decrease Urodynamic Test Reproducibility? (NCT02540798) | Sandwell & West Birmingham Hospitals NHS Trust | 2015-07-01 |
| Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. (NCT02468375) | Samsung Medical Center | 2015-06-01 |
| The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair (NCT02502838) | Icahn School of Medicine at Mount Sinai | 2015-05-01 |
| Urinary Markers of Detrusor Overactivity in Spina Bifida Patients (NCT02852317) | Rennes University Hospital | 2015-03-16 |
| Cystoscopic Ablation Via RF Energy Clinical Trial (NCT02398578) | Amphora Medical, Inc. | 2015-02-01 |
| MIrabegron With oveRACtive bLadder Symptoms in mEn (NCT02361502) | Seoul National University Hospital | 2015-02-01 |
| Mirabegron and Urinary Urgency Incontinence (NCT02495389) | Loyola University | 2015-01-28 |
| A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) (NCT02386072) | Astellas Scientific & Medical Affairs, Inc. | 2015-01-05 |
| Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder (NCT02335853) | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | 2015-01-01 |
| Behavioural Therapy With Checklist for Overactive Bladder (NCT03662893) | Ankara Training and Research Hospital | 2015-01-01 |
| Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB (NCT02485067) | SK Chemicals Co., Ltd. | 2015-01-01 |
| Training and Counseling Program for Overactive Bladder Treatment (NCT03544554) | Biruni University | 2015-01-01 |
| The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder (NCT02315950) | Cedars-Sinai Medical Center | 2014-12-01 |
| Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children (NCT02327936) | Stéphane Bolduc | 2014-12-01 |
| A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (NCT02320773) | Astellas Pharma Europe Ltd. | 2014-11-25 |
| Transcutaneous Posterior Tibial Nerve Electrostimulation With Low Dose Trospium Chloride in OAB in Females (NCT03104101) | Alexandria University | 2014-11-01 |
| The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients (NCT02271607) | Korean Medicine Hospital of Pusan National University | 2014-10-01 |
| Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study (NCT02452879) | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 2014-10-01 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder (NCT02211846) | Astellas Pharma Inc | 2014-09-21 |
| Controlling Urgency Through Relaxation Exercises (NCT02202031) | University of California, San Francisco | 2014-09-01 |
| Foot Neuromodulation for Overactive Bladder in Children (NCT02320201) | Rajeev Chaudhry | 2014-09-01 |
| Audiovisual Stimulus During Urodynamics (NCT02670486) | Women and Infants Hospital of Rhode Island | 2014-08-01 |
| Does Bladder Training Improve the Efficacy of Nerve Stimulation in Women With Refractory Overactive Bladders (NCT02107820) | University Hospital Plymouth NHS Trust | 2014-07-24 |
| Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions (NCT02197533) | Unity Health Toronto | 2014-07-01 |
| Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients (NCT02179099) | UroGen Pharma Ltd. | 2014-07-01 |
| "The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women" (NCT02180048) | Loma Linda University | 2014-07-01 |
| Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder (NCT02129816) | University of Zurich | 2014-05-01 |
| Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women (NCT02143570) | Universidad de Valparaiso | 2014-05-01 |
| A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (NCT02045862) | Astellas Pharma Europe B.V. | 2014-03-17 |
| Foot/Hand Neuromodulation for Overactive Bladder (OAB) (NCT01972061) | Christopher J Chermansky, MD | 2014-03-01 |
| Use of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Maintaining OAB Symptoms Improvement. (NCT02377765) | Liverpool Women's NHS Foundation Trust | 2014-02-01 |